CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million

• CorMedix posted net income of USD 38.6 million, up 87% year over year, as revenue more than doubled to USD 127.43 million.
• Operating income climbed to USD 63.66 million, up 216%, while total operating expenses rose to USD 41.46 million, up 139%.
• Product sales increased to USD 121.92 million, up more than doubled, including DefenCath sales of USD 97.51 million; contract revenue was USD 5.51 million.
• Other expense totaled USD 8.01 million, reflecting USD 3.55 million unrealized loss on Talphera equity securities and USD 4.2 million change in contingent consideration.
• CorMedix flagged a July 1, 2026 shift in DefenCath reimbursement that it expects will significantly reduce net pricing in second-half 2026, while targeting commercialization of REZZAYO in a prophylaxis indication in 2027 if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410098-26-000021), on May 14, 2026, and is solely responsible for the information contained therein.